Stock Market Reviews

Read and share opinions on BAX (Baxter International Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market

Latest News

• Reasons to Retain Baxter International Stock in Your Portfolio Now
  Dec 26, 2025
• Baxter International Inc. (BAX): A Bull Case Theory
  Dec 18, 2025
• BAX Highlights EMR-Integrated Smart Pumps Boost Patient Safety & Care
  Dec 15, 2025
• Baxter International Stock: Is BAX Underperforming the Health Care Sector?
  Dec 12, 2025
• Is Baxter International Offering Long Term Value After Years of Share Price Declines?
  Dec 12, 2025
• How Tender Offers And A Class I Recall At Baxter International (BAX) Have Changed Its Investment Story
  Dec 11, 2025
• Baxter Presents Real-World Data at American Society of Health System Pharmacists Meeting Demonstrating Smart Infusion Pump Electronic Medical Record (EMR) Integration May Improve Patient Safety and Nursing Bedside Productivity
  Dec 11, 2025
• Q3 Earnings Highs And Lows: Baxter (NYSE:BAX) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks
  Dec 11, 2025
• Wall Street Analysts Have Consensus Hold Recommendation For Baxter International Inc. (BAX)
  Dec 9, 2025
• Baxter (BAX): Taking a Fresh Look at Valuation After a Tough Stretch for Shareholders
  Dec 7, 2025
• Baxter Announces Pricing of Tender Offers for 2.600% Senior Notes Due 2026 and 1.915% Senior Notes Due 2027
  Dec 4, 2025
• Baxter Announces Early Tender Results for 2.600% Senior Notes Due 2026 and 1.915% Senior Notes Due 2027
  Dec 4, 2025
• Baxter Issues Recall Notice for Permanent Removal of Life2000 Ventilation
  Dec 2, 2025
• Respiratory Care Devices Market Competitor Analysis Report 2025: Recent Developments, Company Strategies, Sustainability Benchmarking, Product Launches, Key Persons, and Revenue Forecasts
  Nov 24, 2025

BAX News

• Opportunities and Competition in the $1.19 Billion U.S. IV Bags Market, 2025-2033, Featuring Baxter International, Kraton, Technoflex, B. Braun Medical, Sippex IV Bags and More
  Non-PVC, environmentally friendly IV bags are gaining traction due to regulatory and health trends U.S. IV Bags Market U.S. IV Bags Market Dublin, Dec. 29, 2025 (GLOBE NEWSWIRE) -- The "United States IV Bags Market Report by Material Type, Capacity, Chamber Type, States and Company Analysis, 2025-2033" has been added to ResearchAndMarkets.com's offering.The United States IV Bags Market is expected to grow substantially, increasing from US$ 595.98 million in 2024 to US$ 1.19 billion in 2033. This
  Dec 29, 2025
• Reasons to Retain Baxter International Stock in Your Portfolio Now
  BAX is reshaping its portfolio following the divestiture of Kidney Care, focusing on surgical strength, deleveraging and tighter execution to rebuild momentum.
  Dec 26, 2025
• Baxter International Inc. (BAX): A Bull Case Theory
  We came across a bullish thesis on Baxter International Inc. on Value investing subreddit by Mr-Gambini. In this article, we will summarize the bulls’ thesis on BAX. Baxter International Inc.’s share was trading at $19.29 as of December 17th. BAX’s forward P/E was 8.12 according to Yahoo Finance. Baxter International (BAX) is a quintessential “boring but essential” medtech company operating in oligopolistic markets for […]
  Dec 18, 2025
• BAX Highlights EMR-Integrated Smart Pumps Boost Patient Safety & Care
  Baxter shows EMR-integrated smart pumps cut safety alerts and speed IV setup, backed by real-world data from over a million infusions at ASHP 2025.
  Dec 15, 2025
• Is Baxter International Offering Long Term Value After Years of Share Price Declines?
  Wondering if Baxter International is a beaten down healthcare name or a genuine value opportunity at today’s price? Let’s unpack what the market might be missing. The stock has inched up 2.3% over the last week and 3.6% over the past month, but that is against a much steeper backdrop with returns of -35.4% year to date and a -74.0% slide over five years. Investors have been reacting to Baxter’s ongoing portfolio reshaping, including moves to streamline its medical products business and...
  Dec 12, 2025
• Baxter International Stock: Is BAX Underperforming the Health Care Sector?
  Baxter International has lagged the broader health care sector by a wide margin over the past year, and analysts are taking a guarded stance on its outlook.
  Dec 12, 2025
• Q3 Earnings Highs And Lows: Baxter (NYSE:BAX) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks
  Looking back on medical devices & supplies - diversified stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Baxter (NYSE:BAX) and its peers.
  Dec 11, 2025
• Baxter Presents Real-World Data at American Society of Health System Pharmacists Meeting Demonstrating Smart Infusion Pump Electronic Medical Record (EMR) Integration May Improve Patient Safety and Nursing Bedside Productivity
  DEERFIELD, Ill., December 11, 2025--Baxter International Inc. (NYSE:BAX), an innovative leader in infusion therapies and technologies, today announced data in collaboration with The University of Texas Medical Branch (UTMB Health) demonstrating the positive impact of smart infusion pump integration with hospital electronic medical records (EMRs) on patient safety, clinicians' bedside productivity and programming compliance. The analyses of more than one million infusions on Baxter’s Spectrum IQ
  Dec 11, 2025
• How Tender Offers And A Class I Recall At Baxter International (BAX) Have Changed Its Investment Story
  In early December 2025, Baxter International launched cash tender offers to buy back any and all of its 2.600% senior unsecured notes due 2026, and up to US$600 million of its 1.915% senior unsecured notes due 2027, as detailed in an amended offer to purchase document. At the same time, Baxter has been hit with multiple class action lawsuits and an FDA Class I recall over safety defects in its Novum IQ Large Volume Pump, raising fresh questions about product quality oversight and legal risk...
  Dec 11, 2025
• Here’s What Pressured Baxter International (BAX) in Q3
  Pzena Investment Management recently released its third-quarter 2025 commentary for “Pzena Focused Value Strategy.” A copy of the letter can be downloaded here. Driven by optimism about AI and a September rate cut, US broad-based indexes surged in the third quarter. The technology sector was the strongest performer, with growth outpacing value. The Pzena Focused […]
  Dec 10, 2025
• Wall Street Analysts Have Consensus Hold Recommendation For Baxter International Inc. (BAX)
  Baxter International Inc. (NYSE:BAX) is among the Top 15 Lowest P/E Ratios of the S&P 500 in 2025. On December 2, Morgan Stanley analyst Patrick Wood cut his price target on the stock to $15 from $19 while keeping an Underweight rating. Looking ahead to 2026, the analyst told investors in a research note that […]
  Dec 9, 2025
• 3 of Wall Street’s Favorite Stocks We Think Twice About
  The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.
  Dec 8, 2025
• Baxter (BAX): Taking a Fresh Look at Valuation After a Tough Stretch for Shareholders
  Market context and recent performance Baxter International (BAX) has been grinding through a tough stretch, with the stock down sharply over the past year. At the same time, revenue and net income have recently moved in opposite directions, with modest sales growth alongside a headline net loss. See our latest analysis for Baxter International. At around $18.54, Baxter’s 1 month share price return has turned slightly positive, but that sits against a much steeper year to date share price...
  Dec 7, 2025
• Perrigo (PRGO) Down 9.7% Since Last Earnings Report: Can It Rebound?
  Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
  Dec 5, 2025
• SCCM Enhanced Equity Income Fund Sold Baxter Int’l (BAX) Due to Near-Term Headwinds
  Cullen Capital Management, LLC, operating under the name Schafer Cullen Capital Management, Inc. (SCCM), has released its “SCCM Enhanced Equity Income Fund” third-quarter investor letter. A copy of the letter can be downloaded here. US equities continued to rise in the third quarter, with the S&P 500 returning 8.1% while the Russell 1000 Value was up 5.3%. […]
  Dec 5, 2025
• Baxter Announces Early Tender Results for 2.600% Senior Notes Due 2026 and 1.915% Senior Notes Due 2027
  DEERFIELD, Ill., December 04, 2025--Baxter International Inc. (NYSE:BAX) ("Baxter" or the "Company") today announced the early tender results for the previously announced cash tender offers for the 2026 Notes and 2027 Notes (each as defined below). The tender offers are being made pursuant to the terms and conditions set forth in the offer to purchase, dated Nov. 19, 2025, as amended by the Company’s press release dated Nov. 19, 2025 (as it may be further amended or supplemented from time to tim
  Dec 4, 2025
• Baxter Announces Pricing of Tender Offers for 2.600% Senior Notes Due 2026 and 1.915% Senior Notes Due 2027
  DEERFIELD, Ill., December 04, 2025--Baxter International Inc. (NYSE:BAX) ("Baxter" or the "Company") today announced the consideration payable in connection with the previously announced cash tender offers for the 2026 Notes and 2027 Notes (each as defined below). The table below sets forth the Total Consideration (as defined below) for each series of Notes.
  Dec 4, 2025
• 2 Volatile Stocks with Exciting Potential and 1 We Question
  Volatility cuts both ways - while it creates opportunities, it also increases risk, making sharp declines just as likely as big gains. This unpredictability can shake out even the most experienced investors.
  Dec 3, 2025
• Baxter Issues Recall Notice for Permanent Removal of Life2000 Ventilation
  Baxter recalls its Life2000 ventilation system over a serious cybersecurity flaw, pulling the device from the market despite no reported injuries.
  Dec 2, 2025
• Respiratory Care Devices Market Competitor Analysis Report 2025: Recent Developments, Company Strategies, Sustainability Benchmarking, Product Launches, Key Persons, and Revenue Forecasts
  The respiratory care devices market is projected to grow from $24.16 billion in 2024 to $49.19 billion by 2033, at a CAGR of 8.22%. The rise is fueled by increasing cases of respiratory diseases such as asthma, COPD, and sleep apnea. Key devices include nebulizers, inhalers, CPAP machines, and ventilators, crucial for therapy and patient monitoring. Top players like Medtronic, Philips, GE Healthcare, and others are driving innovation. Sustainability efforts are notable among companies like Baxte
  Nov 24, 2025
• Does Baxter Offer Opportunity After a 37% Share Price Drop and Business Restructuring?
  Wondering if Baxter International is a hidden gem or a value trap? You're not alone, especially with the stock catching the eye of investors searching for a bargain. Despite a tough market stretch with a 20.1% dip over the past month and a dramatic 37.4% drop year-to-date, many are asking whether the risk has actually created new upside. In recent weeks, headlines have focused on Baxter's strategic moves, including updates around divestitures and streamlining its business operations. These...
  Nov 22, 2025
• Oracle Names Stephen Rusckowski to the Board of Directors
  Oracle Corporation (NYSE: ORCL) today announced that it unanimously elected Stephen Rusckowski to Oracle's Board of Directors and increased the size of the Board to 14. The election is effective as of November 18, 2025.
  Nov 21, 2025
• CooperCompanies, iRhythm, Baxter, Omnicell, and Neogen Shares Skyrocket, What You Need To Know
  A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to
  Nov 21, 2025
• Baxter Announces Tender Offers for 2026 Notes and 2027 Notes
  DEERFIELD, Ill., November 19, 2025--Baxter International Inc. (NYSE:BAX) ("Baxter" or the "Company") today announced the commencement of tender offers, subject to the terms and conditions described below, to purchase for cash the debt securities issued by Baxter listed in the table below (collectively, the "Securities" and each a "series"). Subject to market conditions, the tender offers are expected to be funded using a portion of the proceeds from a concurrent offering of senior unsecured note
  Nov 19, 2025
• Baxter Announces Increase in Maximum Tender Cap for 1.915% Senior Notes Due 2027
  DEERFIELD, Ill., November 19, 2025--Baxter International Inc. (NYSE:BAX) ("Baxter" or the "Company") today announced that it has increased the maximum purchase price for its $1.45 billion aggregate principal amount outstanding of 1.915% Senior Unsecured Notes due 2027 (the "2027 Notes") that it can repurchase under its previously announced cash tender offer for the 2027 Notes (the "2027 Notes Tender Offer") from $300 million to $600 million, on the terms and subject to the conditions set forth i
  Nov 19, 2025
• How Recent Developments Are Shaping the Evolving Story for Baxter International
  Baxter International’s stock narrative has seen an important update following the latest guidance and financial results. While analysts have maintained their consensus fair value per share at $24.07, the discount rate used in valuation models has risen slightly, from 9.73% to 10.00%. This change reflects a modest increase in perceived risk or cost of capital. Stay tuned to discover how investors can best keep up with evolving perspectives on Baxter’s value drivers and outlook. Analyst Price...
  Nov 19, 2025
• Microscopic Polyangiitis Market Research Report 2025-2035, Competitive Analysis of Roche, Amgen, Teva, Novartis, Baxter, Amerigen Pharma, InflaRx, Biogen, Pfizer, Celltrion
  The Global Microscopic Polyangiitis (MPA) market is experiencing growth driven by the adoption of biologic therapies, which offer targeted mechanisms and improved relapse prevention. MPA, a rare ANCA-associated vasculitis, affects small blood vessels, posing risks to vital organs such as kidneys and lungs. Diagnosis requires ANCA testing and biopsies, with treatment involving corticosteroids, cyclophosphamide, and rituximab, alongside new therapies like avacopan. Despite challenges like high bio
  Nov 18, 2025
• 2 Cash-Producing Stocks Worth Your Attention and 1 That Underwhelm
  A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
  Nov 14, 2025
• Boston Scientific Up 7% in a Month: How Should You Play the Stock?
  BSX's month-long rally, strong Q3 beats and expansion into chronic pain solutions sharpen investor focus.
  Nov 14, 2025
• Argus Research Downgrades Baxter International Inc. (BAX)’s Rating To Hold Following Dividend Cut
  Baxter International Inc. (NYSE:BAX) is among the 13 Most Undervalued Stocks Under $20 to Buy. On October 31, Argus Research downgraded its rating of the stock to Hold from Buy. The adjustment followed the company’s third-quarter fiscal 2025 earnings call a day prior, in which it announced a significant reduction to its quarterly dividend to […]
  Nov 14, 2025
• 3 Reasons to Avoid BAX and 1 Stock to Buy Instead
  Shareholders of Baxter would probably like to forget the past six months even happened. The stock dropped 43.3% and now trades at $18.09. This was partly driven by its softer quarterly results and might have investors contemplating their next move.
  Nov 12, 2025
• Assessing Baxter International’s (BAX) Valuation Following Mixed Q3 Results and New 2025 Guidance
  Baxter International (BAX) has drawn investor attention after posting third quarter results that showed higher sales but a net loss year over year. The company also provided updated guidance calling for moderate sales growth into 2025. See our latest analysis for Baxter International. The latest string of updates from Baxter International, including a modest dividend announcement and confirmation of moderate forward guidance, have not reversed its negative momentum. Even with a small lift in...
  Nov 12, 2025
• 3 Reasons BAX is Risky and 1 Stock to Buy Instead
  Baxter has gotten torched over the last six months - since May 2025, its stock price has dropped 44.3% to $17.76 per share. This was partly driven by its softer quarterly results and might have investors contemplating their next move.
  Nov 11, 2025
• Baxter Declares Quarterly Dividend
  DEERFIELD, Ill., November 11, 2025--Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.01 per share of common stock. The dividend is payable on Jan. 2, 2026, to stockholders of record as of Nov. 28, 2025. The indicated annual dividend rate equates to $0.04 per share of common stock.
  Nov 11, 2025
• Alpha-1 Antitrypsin Deficiency Disease Market Research Report 2025, Competitive Analysis of Shire, GSK, CSL Behring, AstraZeneca, Grifols, Teva Pharma, Boehringer Ingelheim, Kamada, Pfizer, Baxter
  The Alpha-1 Antitrypsin Deficiency Disease market offers opportunities in developing targeted therapies due to an increasing diagnosed patient population, advances in genetic testing, and innovative treatments like enzyme replacement and gene therapies. Growing awareness and technological advancements further drive this niche market. Alpha-1 Antitrypsin Deficiency Disease Market Alpha-1 Antitrypsin Deficiency Disease Market Dublin, Nov. 11, 2025 (GLOBE NEWSWIRE) -- The "Alpha-1 Antitrypsin Defic
  Nov 11, 2025
• The Baxter Foundation Announces $2.6M Grant to Advance STEM Education in Chicagoland Through Partnership With Northwestern University
  DEERFIELD, Ill., November 07, 2025--The Baxter Foundation, the philanthropic arm of Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced the continuation of a partnership with Northwestern University’s School of Education and Social Policy (SESP) to provide science, technology, engineering and math (STEM) programs for students and teachers throughout the Chicagoland area. Supported by a three-year $2.6 million grant from the Foundation, the Baxter Center for Science Edu
  Nov 7, 2025
• 1 Stock Under $50 to Target This Week and 2 We Brush Off
  Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and investors should exercise caution as some have shaky business models.
  Nov 6, 2025
• Baxter’s Q3 Earnings Call: Our Top 5 Analyst Questions
  Baxter’s third quarter results were met with a negative market reaction, as the company delivered top-line growth but missed Wall Street’s revenue expectations. Management attributed performance shortfalls primarily to ongoing challenges in its Infusion Therapies & Technologies division, which faced a continued pause on Novum IQ Large Volume pump shipments, and to softness in U.S. demand for IV solutions. CEO Andrew Hider candidly stated, “We are not satisfied with our current performance,” emph
  Nov 6, 2025
• United States Multiple Myeloma Market Research Report 2025-2033, Profiles of Key Players - Novartis, Abbvie, Sanofi, Johnson and Johnson, Baxter, Pfizer, Takeda, and Bristol-Myers Squibb
  Opportunities in the U.S. multiple myeloma market include leveraging cutting-edge therapies like targeted treatments and immunotherapies, capitalizing on aging demographics, increasing disease awareness, and investing in oncology research. Expansion in combination treatments also offers significant potential. U.S. Multiple Myeloma Market U.S. Multiple Myeloma Market Dublin, Nov. 03, 2025 (GLOBE NEWSWIRE) -- The "United States Multiple Myeloma Market Size, Insights, Analysis, Growth Potential and
  Nov 3, 2025
• What Developments Are Shaping the Narrative for Baxter International’s Future?
  Baxter International’s consensus analyst price target has seen a sharp decline recently, dropping from $28.00 per share to $24.07 per share. This reduction highlights a shift in sentiment, as it stems from mixed expectations about the company’s ability to overcome operational headwinds and sustain long-term growth. Stay tuned to discover how investors and observers can stay informed as the story around Baxter International’s outlook continues to evolve. Stay updated as the Fair Value for...
  Nov 3, 2025
• Is Wall Street Bullish or Bearish on Baxter International Stock?
  As Baxter International has underperformed the broader market over the past year, Wall Street analysts maintain a cautious outlook on the stock’s prospects.
  Nov 3, 2025
• BAX Q3 Deep Dive: Mixed Segment Results and Lowered Guidance Drive Market Reaction
  Healthcare company Baxter International (NYSE:BAX) missed Wall Street’s revenue expectations in Q3 CY2025, but sales rose 5% year on year to $2.84 billion. Next quarter’s revenue guidance of $2.81 billion underwhelmed, coming in 6.5% below analysts’ estimates. Its non-GAAP profit of $0.69 per share was 15.4% above analysts’ consensus estimates.
  Oct 31, 2025
• Why Baxter (BAX) Shares Are Sliding Today
  Shares of healthcare company Baxter International (NYSE:BAX) fell 2.9% in the afternoon session after the stock continued to fall as the company reported mixed third-quarter results, lowered its full-year guidance, and announced a plan to reduce its dividend. While adjusted earnings per share of $0.69 beat expectations, revenue of $2.84 billion fell short of forecasts. The positive earnings were overshadowed by several concerns. The company's gross margin plunged due to product mix shifts and hi
  Oct 31, 2025
• Why Baxter (BAX) Stock Is Falling Today
  Shares of healthcare company Baxter International (NYSE:BAX) fell 13.5% in the morning session after the company reported disappointing third-quarter financial results, which included a miss on revenue and a weak outlook.
  Oct 30, 2025
• Baxter International Inc (BAX) Q3 2025 Earnings Call Highlights: Strong EPS Growth Amid ...
  Baxter International Inc (BAX) reports a 41% increase in adjusted EPS despite facing headwinds in its Infusion Therapies and Technologies division.
  Oct 30, 2025
• Legal and Safety Challenges Might Change the Case For Investing In Baxter International (BAX)
  Baxter International recently reported a third-quarter net loss of US$46 million despite year-on-year sales growth, with results shaped by ongoing legal and product safety challenges. Multiple class action lawsuits have been filed in response to defects and serious patient incidents involving the Novum IQ Large Volume Pump, raising concerns about safety controls and corporate disclosure practices. We will assess how these legal and product safety setbacks are now influencing Baxter...
  Oct 30, 2025
• Why Baxter International Stock Dived by Nearly 15% Today
  The company's mixed quarterly results and uninspiring guidance led to a sell-off.
  Oct 30, 2025

BAX Reviews

• VolatileViking

  Dec 30, 2025

  $BAX This company is like the Swiss Army knife of healthcare—always ready with the right tool to help you feel better!

  Buy

• MarketRender

  Dec 30, 2025

  $BAX With ongoing legal battles and shifting regulations, the pressure is rising. Investors are on edge, holding their breath to see if the fundamentals can hold strong through the storm.

  Sell

• OptionNomad

  Dec 30, 2025

  $BAX In the ever-evolving healthcare landscape, this company feels like a high-stakes game of chance. Will it hit the jackpot or fall flat? The pressure is intense!

  Buy

• MarketMatrix

  Dec 30, 2025

  $BAX This company is so reliable, it could probably deliver pizza on time every time! 🍕

  Buy

• BullishVanguard

  Dec 28, 2025

  $BAX This company’s stock performance could use a serious dose of vitamins.

  Sell

• OptionNomad

  Dec 27, 2025

  $BAX With healthcare demands surging, will this biotech titan rise to the occasion or struggle against regulatory hurdles and market pressures? Tension is in the air!

  Buy

• QuantQuest

  Dec 27, 2025

  $BAX They’re in the business of saving lives! Just don’t forget to put a band-aid on your portfolio just in case.

  Buy

• DiamondHands

  Dec 27, 2025

  $BAX When life gives you lemons, this company gives you life-saving solutions. Who knew lemons could lead to saving lives?

  Buy

• TendieTitan

  Dec 27, 2025

  $BAX This stock is like that kid who always raises their hand in class – reliable, but sometimes you just want them to chill out!

  Sell

• CashOverload

  Dec 26, 2025

  $BAX More like Baxter Internationally Disappointing.

  Sell

• MarginMyth

  Dec 26, 2025

  $BAX Just another overhyped player in a crowded market.

  Sell

• MarketSavage

  Dec 26, 2025

  $BAX A health company with more scandals than solutions.

  Sell

• LiquidityLord

  Dec 24, 2025

  $BAX With a longstanding reputation in the medical products industry, this company is noted for its commitment to innovation and improving patient outcomes. Ongoing investments in research and development may lead to enhanced market performance.

  Buy

• ChartNomad

  Dec 24, 2025

  $BAX With a strong pipeline and recent innovations, this player might just be gearing up for something huge! But can it handle the competition creeping in from all sides? The stakes are high!

  Buy

• TheStockKnight

  Dec 23, 2025

  $BAX With performances like that, it’s a miracle they’re still in business.

  Sell

• BullRunBandit

  Dec 23, 2025

  $BAX Health game's crucial, and they're in the mix, keep an eye on this one.

  Buy

• DividendFrame

  Dec 23, 2025

  $BAX This organization is recognized for its contributions to the medical device and pharmaceutical sectors, demonstrating a strong commitment to improving patient outcomes. Its focus on innovation and quality positions it well in a competitive market.

  Buy

• CandleKnight

  Dec 23, 2025

  $BAX Solid player in the health game, making moves on the court!

  Buy

• MarketMemeLord

  Dec 23, 2025

  $BAX This one's got the moves, makin' waves in the healthcare scene!

  Buy

• StonkDestroyer

  Dec 22, 2025

  $BAX Old news trying to pass as fresh stock.

  Sell

• BearMarketSurvivor

  Dec 22, 2025

  $BAX Health game on point, they’re the quiet players making big waves for better lives!

  Buy

• ProfitFang

  Dec 22, 2025

  $BAX This established healthcare company is known for its diverse portfolio of medical devices and pharmaceuticals. Their ongoing commitment to innovation and quality positions them favorably in the health sector.

  Buy

• ChartNomad

  Dec 21, 2025

  $BAX In a healthcare landscape filled with uncertainty, how will this giant maneuver through the shifting tides? The stakes are critical, and the anxiety is palpable!

  Sell

• AlphaRift

  Dec 20, 2025

  $BAX With a strong reputation in the healthcare sector, this firm is committed to providing innovative medical solutions. Their ongoing efforts in enhancing patient care through advanced products reflect their significance in improving health outcomes globally.

  Buy

• MarketRender

  Dec 20, 2025

  $BAX Healthcare stocks are always in demand, but with regulatory pressures mounting, could this one feel the squeeze? The stakes are high!

  Sell

• GainVector

  Dec 20, 2025

  $BAX As a leader in healthcare products, this company continues to innovate with a strong pipeline of therapies. Its focus on improving patient outcomes positions it favorably in a growing market.

  Buy

• IndexPredator

  Dec 20, 2025

  $BAX A healthcare giant grappling with pressures from all sides! With innovations in the pipeline, the stakes couldn’t be higher! Will they rise to the occasion?

  Buy

• CashCraze

  Dec 20, 2025

  $BAX Recognized for its extensive portfolio in healthcare, this company stands as a key player in improving patient outcomes. Its commitment to research and development could drive future advancements in medical technology.

  Buy

• QuantKnight

  Dec 20, 2025

  $BAX Facing major recalls and regulatory scrutiny, the stakes are high! Investors are on edge, wondering if the recovery will come in time or if the storm will linger longer than expected.

  Sell

• CodeAndCapital

  Dec 20, 2025

  $BAX Like your favorite dad joke, you can always count on this one to deliver the goods when it's needed most!

  Buy

• ShortSavior

  Dec 20, 2025

  $BAX Medical products struggling to find their pulse.

  Sell

• ProfitVortex

  Dec 20, 2025

  $BAX They’re in health, making sure nobody's left behind. Talk about being the mom of pharmaceuticals—always got your back and a tissue ready!

  Buy

• AlphaDecoder

  Dec 20, 2025

  $BAX As a key player in the medical technology sphere, this company showcases a robust portfolio designed to enhance healthcare delivery. Their ongoing commitment to innovation is likely to resonate well with healthcare providers.

  Buy

• ProfitFang

  Dec 19, 2025

  $BAX A leader in the healthcare sector, this organization is committed to enhancing patient outcomes through advanced medical technologies and comprehensive healthcare solutions that cater to diverse needs.

  Buy

• TradeProtocol

  Dec 18, 2025

  $BAX If healthcare were a video game, this company would be the ultimate cheat code for your health!

  Buy

• BagholderElite

  Dec 16, 2025

  $BAX They’re in the game of life, doin' big things for health keepers.

  Buy

• BuyTheDipBro

  Dec 15, 2025

  $BAX Keepin' it fresh in the medical game, you know it!

  Buy

• CapitalRush

  Dec 15, 2025

  $BAX A leader in medical technologies, this company is well-positioned to benefit from the increasing demand for healthcare innovation. Their extensive portfolio supports a strategy centered on enhancing patient care and operational efficiency.

  Buy

• RiskRanger

  Dec 15, 2025

  $BAX This stock is like your trusty old phone—it might not be the latest model, but it’s reliable and has seen you through everything!

  Buy

• TheChartCode

  Dec 13, 2025

  $BAX Imagine if your medicine cabinet played a superhero role. This company is basically the Avenger of health care!

  Buy

• PnLPhantom

  Dec 13, 2025

  $BAX In healthcare, every decision carries immense weight, and the pressure to perform can feel suffocating. There’s no room for error, and the stakes are sky-high!

  Sell

• TradeMatrix

  Dec 13, 2025

  $BAX Failed support retest = bearish.

  Sell

• YieldVector

  Dec 13, 2025

  $BAX Bearish movement accelerating.

  Sell

• WallStreetRogue

  Dec 13, 2025

  $BAX Price reclaiming key moving averages.

  Buy

• ManiaBroker

  Dec 13, 2025

  $BAX Downside continuation formation.

  Sell

• ShortCircuit

  Dec 12, 2025

  $BAX A healthcare giant stumbling over its own feet.

  Sell

• TradeBlitz

  Dec 12, 2025

  $BAX Price action extremely fragile.

  Sell

• CandleKnight

  Dec 12, 2025

  $BAX Bearish continuation nearly confirmed.

  Sell

• YOLOHold

  Dec 11, 2025

  $BAX Heavy inflows into this name.

  Buy

• YOLOTrader69

  Dec 11, 2025

  $BAX Playin' in the health game, they got that hustle!

  Sell

• TradePhantom

  Dec 11, 2025

  $BAX Just what we need, another company to mishandle our health.

  Sell

• DividendHunter

  Dec 11, 2025

  $BAX Bearish price expansion imminent.

  Sell

• TheStockKnight

  Dec 11, 2025

  $BAX Short sellers gaining confidence.

  Sell

• DividendGhost

  Dec 11, 2025

  $BAX Bearish divergence appearing on indicators.

  Sell

• RiskDriver

  Dec 11, 2025

  $BAX Heavy downside liquidity grab forming.

  Sell

• MarginLogic

  Dec 11, 2025

  $BAX Fear dominating the tape.

  Sell

• ShortSavage

  Dec 11, 2025

  $BAX Momentum favoring longs.

  Buy

• HoldTheLine

  Dec 11, 2025

  $BAX This joint's got the moves, keepin' healthcare flowin' smooth!

  Buy

• MemeInvestor

  Dec 10, 2025

  $BAX Picture this stock as that one friend who always remembers your birthday and brings cake—taking care of your health like a champ!

  Buy

• RiskRaider

  Dec 10, 2025

  $BAX This company is a classic case of too many cooks.

  Sell

• BearishBoi

  Dec 10, 2025

  $BAX With medical supplies that literally save lives, this company is like the superhero of healthcare! Cape not included.

  Buy

• TheEarningsBeast

  Dec 10, 2025

  $BAX They’re like your health-conscious friend who always has the best first-aid tips and quality products—even if you’re just looking for a band-aid!

  Buy

• WallStreetVandal

  Dec 9, 2025

  $BAX Nothing like a giant in healthcare with a questionable reputation.

  Sell

• MarginMarauder

  Dec 9, 2025

  $BAX This stock is like that dependable friend who always shows up with snacks for movie night. Total MVP move!

  Buy

• FinTechFrost

  Dec 9, 2025

  $BAX Like a classic flick you can watch over and over—this stock is familiar, trustworthy, and always delivers feels!

  Buy

• RiskAssassin

  Dec 9, 2025

  $BAX Strong bearish drift underway.

  Sell

• CapitalCrusher

  Dec 9, 2025

  $BAX Heavy bid stacks showing up.

  Buy

• QuantQuest

  Dec 9, 2025

  $BAX Strong reversal candle printed today.

  Buy

• TheMemeInvestor

  Dec 9, 2025

  $BAX Upward pressure not slowing down.

  Buy

• StockSpecter

  Dec 8, 2025

  $BAX A healthcare giant that's lost its way.

  Sell

• ProfitLancer

  Dec 8, 2025

  $BAX Taking more risks than a toddler with scissors.

  Sell

• MarketGlitch

  Dec 8, 2025

  $BAX With healthcare demands skyrocketing, this player could either soar or crash hard. The stakes are high, and every decision counts! Are they ready for the rollercoaster ahead?

  Sell

• CashOverload

  Dec 8, 2025

  $BAX This health giant is anything but a lifesaver—drown away your hopes.

  Sell

• AlphaVandal

  Dec 8, 2025

  $BAX This company might as well be handing out band-aids for its problems.

  Sell

• BullishBerserker

  Dec 8, 2025

  $BAX Every day feels like a new challenge, and the pressure to deliver is immense. Are they ready to tackle the hurdles ahead, or will it crumble?

  Sell

• VolatilityNomad

  Dec 8, 2025

  $BAX Feeling like a health risk in this market.

  Sell

• MarketWolf

  Dec 7, 2025

  $BAX With healthcare demands skyrocketing, can this giant keep up the pace, or will it falter under pressure? Time is ticking, and every moment counts!

  Buy

• TradeNinja

  Dec 7, 2025

  $BAX Think of this company as the dependable friend who always brings snacks to the party—can’t go wrong with that kind of support!

  Buy

• CapitalFrame

  Dec 6, 2025

  $BAX This healthcare giant continues to demonstrate resilience with its extensive portfolio of medical products and solutions. As global health initiatives expand, its innovative approach ensures it remains a key contributor to patient care.

  Buy

• CandleKnight

  Dec 6, 2025

  $BAX Bullish consolidation forming.

  Buy

• BuyLowBro

  Dec 6, 2025

  $BAX Breakout traps shorts — bullish outcome ahead.

  Buy

• GainMachine

  Dec 5, 2025

  $BAX This company is like a superhero for your health—saving the day one IV bag at a time! Who needs capes?

  Buy

• StonkViking

  Dec 5, 2025

  $BAX They got the game on lock with solid health gear, no doubt.

  Buy

• FinTechFrost

  Dec 4, 2025

  $BAX This stock is like that reliable friend who always has your back—a true lifesaver when the going gets tough!

  Buy

• TrendScript

  Dec 4, 2025

  $BAX This company is making significant strides in the healthcare sector, showcasing a robust pipeline that indicates potential for future growth. Their commitment to innovation and improving patient outcomes positions them well in a competitive landscape.

  Buy

• YieldVector

  Dec 4, 2025

  $BAX Trend exhaustion visible at top.

  Sell

• ProfitVandal

  Dec 4, 2025

  $BAX Long setup looks extremely clean.

  Buy

• ChartNomad

  Dec 4, 2025

  $BAX Trendline support holding strong.

  Buy

• BagholderElite

  Dec 4, 2025

  $BAX Bullish candle structure forming.

  Buy

• FiscalBinary

  Dec 4, 2025

  $BAX Early signs of long-term breakout.

  Buy

• CapitalCreep

  Dec 4, 2025

  $BAX Sellers tightening grip on price.

  Sell

• StockNova

  Dec 4, 2025

  $BAX A leader in medical products, this organization consistently demonstrates its commitment to innovation and patient care. Their extensive portfolio of therapies reflects a proactive strategy to address complex health challenges.

  Buy

• EarningsEcho

  Dec 3, 2025

  $BAX When it comes to keeping folks healthy, this stock is like a superhero in scrubs! Just needs a cape and a catchy theme song.

  Buy

• StonkZombie

  Dec 3, 2025

  $BAX Solid in the health scene, steady as she goes, always a reliable face.

  Buy

• WallStreetGrim

  Dec 3, 2025

  $BAX This established healthcare player is aligned with critical trends in medical innovation and patient safety. Its diverse portfolio and commitment to quality may ensure continued relevance and growth in a rapidly evolving market.

  Buy

• StonkSamurai

  Dec 2, 2025

  $BAX This joint's got mad potential, keep an eye on it!

  Buy

• StonkViking

  Dec 2, 2025

  $BAX Always in the game, a steady player you can count on.

  Buy

• VolatileViking

  Dec 1, 2025

  $BAX Like a superhero for health, saving the day one patient at a time—cape not included!

  Buy

• TickerFlux

  Dec 1, 2025

  $BAX The tension in the healthcare sector is palpable! Every news release feels like a ticking time bomb, and it's hard to breathe with all this pressure!

  Buy

• BullRunBandit

  Nov 30, 2025

  $BAX They got the goods for the health hustle, keepin’ folks feelin’ right.

  Buy

• BagholderPrime

  Nov 30, 2025

  $BAX If health care was a superhero movie, this company would be the wise old mentor training the young heroes—smart choices all around!

  Buy

• BullishSniper

  Nov 30, 2025

  $BAX This company's got the healthcare vibes, like a superhero for our bodies, but without the cape! Just don’t ask them to save your lunch.

  Buy

• FUDCrusher

  Nov 29, 2025

  $BAX Solid in the health game, they got the moves to impress, no doubt!

  Buy

• PriceBreaker

  Nov 29, 2025

  $BAX This company has a long-standing reputation for reliability in the medical device sector, consistently delivering essential products that improve patient outcomes. Their ongoing investment in research and development indicates a proactive approach to addressing future healthcare challenges.

  Buy

• OptionRogue

  Nov 28, 2025

  $BAX This company is at the forefront of innovative healthcare solutions, focusing on delivering essential products that improve patient outcomes. With a strong commitment to research and development, its future prospects look promising in an ever-evolving market.

  Buy

• ChartSaber

  Nov 28, 2025

  $BAX Healthcare heavyweight, always making waves in the game.

  Buy

• MarketMarauder

  Nov 27, 2025

  $BAX A company stuck in the past with outdated ideas.

  Sell

• EquityAssault

  Nov 25, 2025

  $BAX It’s all just smoke and mirrors at this point.

  Sell

• TradeFrenzy

  Nov 25, 2025

  $BAX Stuck in the past while others move ahead.

  Sell

• LiquidityLord

  Nov 25, 2025

  $BAX With a focus on enhancing patient care through its diverse medical products, this company remains a key player in the healthcare sector. Its continuous innovation and global reach contribute to a solid market presence.

  Buy

• TheEarningsBeast

  Nov 24, 2025

  $BAX Delivering healthcare products like pizza delivery, but with less cheese and more needles!

  Sell

• BearBreaker

  Nov 24, 2025

  $BAX A healthcare giant that's lost its innovation spark.

  Sell

• DividendDemon

  Nov 23, 2025

  $BAX This stock brings all the feels—like a warm blanket on a chilly day, but don’t get too cozy too fast!

  Sell

• CodeAndCapital

  Nov 22, 2025

  $BAX If this stock were a superhero, it’d totally be the one who saves the day and definitely has its cape ready at all times!

  Buy

• BuyLowBoi

  Nov 22, 2025

  $BAX A solid player, but it’s feelin' a little slow on the draw.

  Sell

• PriceBreaker

  Nov 22, 2025

  $BAX This company's commitment to innovation within the healthcare sector positions it well for future growth, particularly with its expanding product lines and global reach. Investors may find it appealing due to its consistent performance and strong market presence.

  Buy

• BullRunBoss

  Nov 22, 2025

  $BAX This company keeps the healthcare gears turning—because who doesn’t want a strong support system with a side of science?

  Buy

• LiquidLegend

  Nov 22, 2025

  $BAX Making sure you don’t just survive, but thrive—like a health coach who actually knows their stuff!

  Buy

• CapitalCrusher

  Nov 22, 2025

  $BAX This company keeps the world healthy like my mom keeps the fridge stocked—always something good for you in there!

  Buy

• FiscalFury

  Nov 21, 2025

  $BAX It’s like the dependable friend who always has snacks at a party—can’t go wrong with a solid choice!

  Buy

• StonkSlayer

  Nov 21, 2025

  $BAX This stock is like your overachieving cousin—always doing something impressive, but can you keep up?

  Buy

• BagholderPrime

  Nov 20, 2025

  $BAX You know that reliable friend who brings snacks to every hangout? This stock is the snack that keeps on giving!

  Buy

• MarketNomad

  Nov 20, 2025

  $BAX Just another healthcare company drowning in lawsuits.

  Sell

• TendieTitan

  Nov 19, 2025

  $BAX They’re in the business of saving lives – like a superhero, but without the cape and tights!

  Buy

• TheAlphaDagger

  Nov 18, 2025

  $BAX This giant in the healthcare world seems to be wrestling with market pressures like a heavyweight champ. Will they come out on top, or are they going down for the count?

  Sell

• CapitalNova

  Nov 18, 2025

  $BAX This organization is recognized for its commitment to improving patient outcomes through robust product offerings. Consistent investment in research and development signifies a strong dedication to innovation in the healthcare sector.

  Buy

• BullishSniper

  Nov 18, 2025

  $BAX This company is like a reliable pizza delivery—sometimes slow, but you know it’ll eventually get you what you need!

  Buy

• RiskAssassin

  Nov 18, 2025

  $BAX Amidst the healthcare frenzy, there are whispers of innovation and concern. The stakes are high as this player stands at the intersection of breakthrough and backlash. Will it prove resilient or falter in the face of scrutiny?

  Sell

• BuyTheDipBro

  Nov 17, 2025

  $BAX In the health game strong, but the competition's fierce, ya feel?

  Sell

• TradeProtocol

  Nov 16, 2025

  $BAX Healthcare needs good vibes as much as we do! Let’s hope this stock is more than just band-aids and dreams.

  Sell

• HedgeKnight

  Nov 15, 2025

  $BAX This is the kind of stock that makes you feel like you’ve got a superhero on your team. They’re here to save the day, one medical device at a time!

  Buy

• YOLOTrader

  Nov 15, 2025

  $BAX Healthcare? More like health-cool! This stock is like the superhero of the medical world, cape included.

  Buy

• TradeHex

  Nov 14, 2025

  $BAX Renowned for its extensive portfolio of life-saving products, this organization continues to lead in healthcare innovation, reflecting a strong commitment to improving patient outcomes across the globe.

  Buy

• CashCraze

  Nov 14, 2025

  $BAX This company is recognized for its commitment to innovative healthcare solutions and has a robust portfolio that caters to diverse medical needs. Its ongoing investments in research and development are likely to enhance its market position and drive future growth.

  Buy

• MarginLogic

  Nov 14, 2025

  $BAX Established as a leader in healthcare solutions, the company is strategically enhancing its portfolio to meet growing global health needs. Recent partnerships and product launches demonstrate a proactive approach to market demands.

  Buy

• MarketRender

  Nov 14, 2025

  $BAX In the cutthroat world of healthcare, this giant faces constant scrutiny and challenges. Regulatory pressures and market dynamics are tightening, making every move critical for survival and growth!

  Sell

• BuyTheDipBro

  Nov 14, 2025

  $BAX This one’s got the game solid, makin' waves in health care, ya dig?

  Buy

• BuyLowBro

  Nov 13, 2025

  $BAX This company's like that dependable friend who always has your back, even when you're feeling under the weather. 🤒❤️

  Buy

• CashWraith

  Nov 13, 2025

  $BAX In the realm of medical supplies, this company could be a frontrunner. But with so many competitors nipping at their heels, can they maintain their edge?

  Buy

• TheTradingVerse

  Nov 13, 2025

  $BAX A leader in the medical device space, this company is well-positioned to leverage advancements in healthcare technology and address the growing needs of diverse patient populations.

  Buy

• PnLPhantom

  Nov 12, 2025

  $BAX In a market filled with health concerns and regulatory scrutiny, their next moves are crucial. It's a high-stakes game that could easily tip one way or the other!

  Buy

• BuyLowBoi

  Nov 12, 2025

  $BAX They got the skills to keep your health on point, no lie!

  Buy

• YieldMyth

  Nov 12, 2025

  $BAX A heavyweight in health, always on the tippity top!

  Buy

• StockStrider

  Nov 12, 2025

  $BAX This company is recognized for its commitment to developing innovative solutions in the healthcare space. With a strong pipeline of products and a focus on improving patient outcomes, it remains a key player in its industry as demand for healthcare services continues to grow.

  Buy

• PriceBreaker

  Nov 11, 2025

  $BAX Known for its contributions to health care, this firm emphasizes innovation in products and services that improve patient outcomes. Its strategic partnerships and R&D investments position it well for future advancements.

  Buy

• YieldWarden

  Nov 10, 2025

  $BAX Regulatory hurdles and market demands feel like a relentless storm. This company must navigate these treacherous waters with precision, or risk capsizing in a sea of competition!

  Sell

• FinTechNomad

  Nov 10, 2025

  $BAX Facing scrutiny over product recalls and regulatory challenges, this healthcare giant feels like it's walking a tightrope. Can they stabilize their operations, or will the turbulence send stockholders into a panic?

  Sell

• BuyLowBro

  Nov 10, 2025

  $BAX This company is like that reliable old car – it may not be flashy, but it gets you where you need to go!

  Buy

• GainsJester

  Nov 9, 2025

  $BAX Healthcare hustle on fleek, they’re bringing the heat.

  Buy